Search Results - "Stauder, R."

The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy by Hamaker, Marije E., Mitrovic, M., Stauder, R.

“…The G8 screening tool was developed to separate fit older cancer patients who were able to receive standard treatment from those that should undergo a…”
Get full text

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines by Aapro, M, Beguin, Y, Bokemeyer, C, Dicato, M, Gascón, P, Glaspy, J, Hofmann, A, Link, H, Littlewood, T, Ludwig, H, Österborg, A, Pronzato, P, Santini, V, Schrijvers, D, Stauder, R, Jordan, K, Herrstedt, J

Get full text

The relevance of a geriatric assessment for elderly patients with a haematological malignancy – A systematic review by Hamaker, M.E, Prins, M.C, Stauder, R

“…Abstract Background Geriatric assessment is increasingly used to assess the health status of older cancer patients. We set out to assemble all available…”
Get full text

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials by Platzbecker, U., Fenaux, P., Adès, L., Giagounidis, A., Santini, V., van de Loosdrecht, A.A., Bowen, D., de Witte, T., Garcia-Manero, G., Hellström-Lindberg, E., Germing, U., Stauder, R., Malcovati, L., Sekeres, Mikkael A., Steensma, David P., Gloaguen, S.

“…The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group…”
Get full text

Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary by Morrison, V.A., Hamlin, P., Soubeyran, P., Stauder, R., Wadhwa, P., Aapro, M., Lichtman, S.M.

“…Diffuse large B-cell lymphoma (DLBCL) is a treatable and potentially curable malignancy that is increasing in prevalence in the elderly. Until recently, older…”
Get full text

ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma by Buske, C., Hutchings, M., Ladetto, M., Goede, V., Mey, U., Soubeyran, P., Spina, M., Stauder, R., Trněný, M., Wedding, U., Fields, P., Buske, Christian, Dreyling, Martin, Ferreri, Andrés J M, Fields, Paul, Gaidano, Gianluca, Goede, Valentin, Hutchings, Martin, Ladetto, Marco, Le Gouill, Steven, Luminari, Stefano, Mey, Ulrich, de Nully Brown, Peter, Pfreundschuh, Michael, Pott, Christiane, Schmitz, Norbert, Soubeyran, Pierre, Spina, Michele, Stauder, Reinhard, Balari, Anna Sureda, Trněný, Marek, van Imhoff, Gustaaf, Walewski, Jan, Wedding, Ulrich, Zamò, Alberto, Zucca, Emanuele

“…The European Society for Medical Oncology (ESMO) consensus conference on mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June…”
Get full text

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force by Stauder, R., Eichhorst, B., Hamaker, M.E., Kaplanov, K., Morrison, V.A., Österborg, A., Poddubnaya, I., Woyach, J.A., Shanafelt, T., Smolej, L., Ysebaert, L., Goede, V.

“…Chronic lymphocytic leukemia (CLL) mainly affects older people: the median age at diagnosis is > 70 years. Elderly patients with CLL are heterogeneous with…”
Get full text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts by Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G

“…Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic…”
Get full text

Fatigue at baseline is associated with geriatric impairments and represents an adverse prognostic factor in older patients with a hematological malignancy by Hofer, F., Koinig, K. A., Nagl, L., Borjan, B., Stauder, R.

“…Prospective data on fatigue in elderly persons with a hematological malignancy are rare. We aimed to determine the prevalence of fatigue and its association…”
Get full text

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) by Della Porta, M G, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S M M, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, Cazzola, M

“…A risk-adapted treatment strategy is mandatory for myelodysplastic syndromes (MDS). We refined the World Health Organization (WHO)-classification-based…”
Get full text

Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group by Sperr, W. R., Wimazal, F., Kundi, M., Baumgartner, C., Nösslinger, T., Makrai, A., Stauder, R., Krieger, O., Pfeilstöcker, M., Valent, P.

“…Background: The evaluation of comorbidity is of increasing importance in patients with hematologic disorders. Patients and methods: In the present study, the…”
Get full text

Clinical judgement and geriatric assessment for predicting prognosis and chemotherapy completion in older patients with a hematological malignancy by Hamaker, M. E., Augschoell, J., Stauder, R.

“…Prior research has focused on comparing clinical judgment with geriatric assessments in identifying potentially unfit patients or the prognostic value of…”
Get full text

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification by Nachtkamp, K., Strupp, C., Vukelja, M., Kasprzak, A., Haase, D., Ganster, C., Hildebrandt, B., Betz, B., Giagounidis, A., Aul, C., Blum, S., Hofmann, W. K., Pfeilstöcker, M., Valent, P., Lübbert, M., Seidl, M., Rudelius, M., Stauder, R., Krieger, O., Götze, K. S., Bobak, J., Kündgen, A., Schulz, F., Dietrich, S., Kobbe, G., Gattermann, N., Germing, U.

Get full text

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines by Aapro, M, Beguin, Y, Bokemeyer, C, Dicato, M, Gascón, P, Glaspy, J, Hofmann, A, Link, H, Littlewood, T, Ludwig, H, Österborg, A, Pronzato, P, Santini, V, Schrijvers, D, Stauder, R, Jordan, K, Herrstedt, J

Get full text

Relevance of age and comorbidities in risk scoring and decision making in MDS in the elderly by Stauder, R

Get full text

Azacitidine is removed effectively by hemodialysis by Beer, A. G. E, Laille, E., Neuwirt, H., Mayer, G., Stauder, R.

Get full text

On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? by Hamaker, M.E., Stauder, R., van Munster, B.C.

“…Cancer societies and research cooperative groups worldwide have urged for the development of cancer trials that will address those outcome measures that are…”
Get full text

F14 MDS: a challenge, especially in elderly patients by Stauder, R

Get full text

Hematological malignancies in the elderly by Stauder, R

Get full text

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study by Germing, U, Lauseker, M, Hildebrandt, B, Symeonidis, A, Cermak, J, Fenaux, P, Kelaidi, C, Pfeilstöcker, M, Nösslinger, T, Sekeres, M, Maciejewski, J, Haase, D, Schanz, J, Seymour, J, Kenealy, M, Weide, R, Lübbert, M, Platzbecker, U, Valent, P, Götze, K, Stauder, R, Blum, S, Kreuzer, K-A, Schlenk, R, Ganser, A, Hofmann, W-K, Aul, C, Krieger, O, Kündgen, A, Haas, R, Hasford, J, Giagounidis, A

“…Myelodysplastic syndromes (MDS) with del(5q) are considered to have a benign course of the disease. In order to address the issue of the propensity of those…”
Get full text